SSA
IPSC icon

Schonfeld Strategic Advisors’s Century Therapeutics IPSC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-93,085
Closed -$389K – 2348
2024
Q1 		$389K Buy
+93,085
New +$394K ﹤0.01% 1563
2022
Q1 		– Sell
-12,300
Closed -$195K – 2740
2021
Q4 		$195K Sell
12,300
-1,300
-10% -$24.4K ﹤0.01% 1747
2021
Q3 		$342K Sell
13,600
-4,500
-25% -$122K ﹤0.01% 1460
2021
Q2 		$531K Buy
+18,100
New +$459K 0.01% 1161

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Schonfeld Strategic Advisors's IPSC Position: Q2 2024 in Review

Schonfeld Strategic Advisors sold out of Century Therapeutics (IPSC) in Q2 2024, closing a stake of 93,085 shares — an estimated $389K sold.

Schonfeld Strategic Advisors first reported a position in IPSC in Q2 2021 and held it in 4 quarters. The position peaked at $531K in Q2 2021. 61 funds tracked by Wall St. Rank hold IPSC as of Q2 2024.

  • Schonfeld Strategic Advisors reported no remaining Century Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 93,085 Century Therapeutics shares in Q2 2024, an estimated $389K.
  • Schonfeld Strategic Advisors first reported a position in Century Therapeutics in Q2 2021 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Century Therapeutics position peaked at $531K in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.